Abstract

Apolipoprotein A-I (ApoA-I) is the major protein of high density lipoprotein (HDL) particles and has a crucial role in reverse cholesterol transport (RCT). It has been postulated that elevating production of de novo ApoA-I might translate into the formation of new functional HDL particles that could lower cardiovascular disease (CVD) risk via RCT. During inflammation, serum ApoA-I concentrations are reduced, which contributes to the development of dysfunctional HDL particles as Serum Amyloid A (SAA) overtakes the position of ApoA-I within the HDL particles. Therefore, instead of elevating serum HDL cholesterol concentrations, rescuing lower serum ApoA-I concentrations could be beneficial in both normal and inflamed conditions. Several nutritional compounds, amongst others short chain fatty acids (SCFAs), have shown their capacity to modulate hepatic lipoprotein metabolism. In this review we provide an overview of HDL and more specific ApoA-I metabolism, SCFAs physiology and the current knowledge regarding the influence of SCFAs on ApoA-I expression and synthesis in human liver cells. We conclude that the current evidence regarding the effect of SCFAs on ApoA-I transcription and secretion is promising, however there is a need to investigate which dietary fibres could lead to increased SCFAs formation and consequent elevated ApoA-I concentrations.

Highlights

  • Cardiovascular disease (CVD) is currently the leading cause of deaths worldwide [1,2]

  • CVD risk profiles are characterized by prolonged dyslipidemia, which leads to progressive atherosclerosis [4]

  • To understand the underlying mechanisms as to how short chain fatty acids (SCFAs) rescued the reduction in Apolipoprotein A-I (ApoA-I) mRNA production during inflammation, Tayyeb et al again evaluated the effects of butyrate on the bromodomain and extra-terminal (BET) and PPARα pathways

Read more

Summary

Introduction

Cardiovascular disease (CVD) is currently the leading cause of deaths worldwide [1,2]. Large scale intervention studies that elevated serum HDL-C concentrations failed to lower CVD development [6,7] This resulted in the development of alternative explanations how to position the link between the HDL-C fraction and CVD risk, what we nowadays call “functional HDL-C”. This implies that it is not elevating HDL-C concentrations that is protective but increasing the functionality of HDL particles that makes them able to fulfil a protective role. Increasing the endogenous production of ApoA-I protein and supplying the serum with fresh empty HDL particles, especially under inflammatory conditions, seems warranted to lower CVD risk and counter dyslipidemia. We present the current evidence regarding the influence of SCFAs on hepatic ApoA-I transcription and production under normal and metabolically disturbed conditions such as inflammation

ApoA-I as Interesting Target to Modulate HDL Metabolism
Potential Effects of SCFAs on ApoA-I Metabolism
Inflammation and ApoA-I
Antibiotics and ApoA-I
Limitations and Future
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call